-
公开(公告)号：US20120077690A1
公开(公告)日：2012-03-29
申请号：US13235005
申请日：2011-09-16
申请人： Kai Singbartl , John A. Kellum, JR.
发明人： Kai Singbartl , John A. Kellum, JR.
IPC分类号： C40B30/04 , G01N33/566
摘要： This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor β1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.
摘要翻译： 本发明涉及肾脏疾病的预防和治疗领域。 可以根据长期透析的需要或期望来定制肾脏疾病的治疗。 例如，长期透析治疗的预测可以通过监测与慢性肾脏疾病发展有关的尿生物标志物来确定。 例如，测量透明质酸，死亡受体5和/或转化生长因子1的约14天的标准化时间过程可用于确定患有急性肾损伤的患者的恢复与非恢复的风险。
-
2.发明申请Urine Biomarkers For Prediction Of Recovery After Acute Kidney Injury: Proteomics 有权尿液生物标志物预测急性肾损伤后恢复：蛋白质组学公开(公告)号：US20130323751A1
公开(公告)日：2013-12-05
申请号：US13981747
申请日：2012-01-20
申请人： Kai Singbartl , John A. Kellum, JR.
发明人： Kai Singbartl , John A. Kellum, JR.
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/52 , G01N2800/60
摘要： This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.
摘要翻译： 本发明涉及肾脏疾病的预防和治疗领域。 肾脏疾病的治疗可以根据肾脏恢复的需要或预期来定制。 例如，通过监测与慢性肾脏疾病发展相关的尿生物标志物可以确定肾脏恢复。 例如，测量尿蛋白的大约十四天的标准化时间过程可用于确定患有急性肾损伤的患者的恢复与非恢复的风险。 或者，本发明描述了标志蛋白表达谱，以确定肾恢复和/或肾不恢复的可能性。
-
公开(公告)号：US10557856B2
公开(公告)日：2020-02-11
申请号：US13235005
申请日：2011-09-16
申请人： Kai Singbartl , John A. Kellum, Jr.
发明人： Kai Singbartl , John A. Kellum, Jr.
IPC分类号： G01N33/68
摘要： This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor β1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.
-
公开(公告)号：US08501489B2
公开(公告)日：2013-08-06
申请号：US12565483
申请日：2009-09-23
申请人： Kai Singbartl , John A. Kellum, Jr.
发明人： Kai Singbartl , John A. Kellum, Jr.
CPC分类号： G01N33/5308 , A61M1/14 , G01N33/543 , G01N2400/40 , G01N2800/347 , G01N2800/52 , Y10T436/00 , Y10T436/14 , Y10T436/142222 , Y10T436/143333
摘要： This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.
摘要翻译： 本发明涉及肾脏疾病的预防和治疗领域。 可以根据长期透析的需要或期望来定制肾脏疾病的治疗。 例如，长期透析治疗的预测可以通过监测与慢性肾脏疾病发展有关的尿生物标志物来确定。 例如，可以使用透明质酸的归一化时间过程来确定是否患有急性肾损伤的患者将需要长期透析。
-
公开(公告)号：US20080281248A1
公开(公告)日：2008-11-13
申请号：US12061562
申请日：2008-04-02
CPC分类号： A61M25/007 , A61M1/008 , A61M1/1678 , A61M1/34 , A61M1/3653 , A61M1/3659 , A61M1/3679 , A61M5/007 , A61M25/0021 , A61M25/0041 , A61M25/0054 , A61M25/0068 , A61M25/008 , A61M25/10 , A61M2202/0007 , A61M2202/0014 , A61M2202/0468 , A61M2205/3334
摘要： The invention provides a system and a method for removal of contrast from blood. In one aspect, the invention provides a catheter for removal of contrast from the veins that drain the cerebral circulation. In a second aspect, the invention provides a method for removing contrast from blood by contacting the blood with a sorbent.
摘要翻译： 本发明提供一种从血液中去除对比度的系统和方法。 一方面，本发明提供一种用于从排出大脑循环的静脉中除去对比度的导管。 在第二方面，本发明提供了一种通过使血液与吸附剂接触来从血液中除去对比度的方法。
-
6.发明授权Urine biomarkers for prediction of recovery after acute kidney injury: proteomics 有权用于预测急性肾损伤后恢复的尿生物标志物：蛋白质组学公开(公告)号：US09551720B2
公开(公告)日：2017-01-24
申请号：US13981747
申请日：2012-01-20
申请人： Kai Singbartl , John A. Kellum, Jr.
发明人： Kai Singbartl , John A. Kellum, Jr.
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/52 , G01N2800/60
摘要： This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.
摘要翻译： 本发明涉及肾脏疾病的预防和治疗领域。 肾脏疾病的治疗可以根据肾脏恢复的需要或预期来定制。 例如，通过监测与慢性肾脏疾病发展相关的尿生物标志物可以确定肾脏恢复。 例如，测量尿蛋白的大约十四天的标准化时间过程可用于确定患有急性肾损伤的患者的恢复与非恢复的风险。 或者，本发明描述了确定肾脏恢复和/或肾脏不恢复的可能性的特征蛋白质表达谱。
-
公开(公告)号：US20100081148A1
公开(公告)日：2010-04-01
申请号：US12565483
申请日：2009-09-23
申请人： Kai Singbartl , John A. Kellum, JR.
发明人： Kai Singbartl , John A. Kellum, JR.
IPC分类号： G01N33/53
CPC分类号： G01N33/5308 , A61M1/14 , G01N33/543 , G01N2400/40 , G01N2800/347 , G01N2800/52 , Y10T436/00 , Y10T436/14 , Y10T436/142222 , Y10T436/143333
摘要： This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.
摘要翻译： 本发明涉及肾脏疾病的预防和治疗领域。 可以根据长期透析的需要或期望来定制肾脏疾病的治疗。 例如，长期透析治疗的预测可以通过监测与慢性肾脏疾病发展有关的尿生物标志物来确定。 例如，可以使用透明质酸的归一化时间过程来确定是否患有急性肾损伤的患者将需要长期透析。
-
公开(公告)号：US08398576B2
公开(公告)日：2013-03-19
申请号：US12061562
申请日：2008-04-02
CPC分类号： A61M25/007 , A61M1/008 , A61M1/1678 , A61M1/34 , A61M1/3653 , A61M1/3659 , A61M1/3679 , A61M5/007 , A61M25/0021 , A61M25/0041 , A61M25/0054 , A61M25/0068 , A61M25/008 , A61M25/10 , A61M2202/0007 , A61M2202/0014 , A61M2202/0468 , A61M2205/3334
摘要： The invention provides a system and a method for removal of contrast from blood. In one aspect, the invention provides a catheter for removal of contrast from the veins that drain the cerebral circulation. In a second aspect, the invention provides a method for removing contrast from blood by contacting the blood with a sorbent.
摘要翻译： 本发明提供一种从血液中去除对比度的系统和方法。 一方面，本发明提供一种用于从排出大脑循环的静脉中除去对比度的导管。 在第二方面，本发明提供了一种通过使血液与吸附剂接触来从血液中除去对比度的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.025 秒)
